BioSpace News Archive

Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that Asa Abeliovich, M.D., Ph.D., Founder and Chief Executive Officer of Prevail, will present at the virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

BERG, a clinical-stage biotech that employs artificial intelligence (AI) to investigate diseases and develop innovative treatments, today announced two major medical/clinical research developments on pancreatic ductal adenocarcinoma (PDAC) to be presented virtually at the European Society for Medical Oncology (ESMO) 2020 Congress taking place from September 19-21, 2020.

Kala Pharmaceuticals, Inc., announced that the Company granted non-statutory stock options to a new employee as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635.

Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that on September 17, 2020,

OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”) announced today that it has changed the venue of its 2020 Annual Meeting of Stockholders due to continuing health and safety considerations arising from the COVID-19 pandemic.

iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today provided commentary on the Center for Medicare and Medicaid Services’ (CMS) Radiation Oncology alternative payment model (RO-APM), which was published today.

“Lonza’s subject matter experts enjoyed working with LamKap’s technical team to identify specific molecule needs and design a tailored work package suitable to achieve their goals.

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. announced the publication of detailed results from the Phase III JAVELIN Bladder 100 study online ahead of print in The New England Journal of Medicine.

Independent central review confirmed responses include 1 complete response, 12 partial responses and 33 stable disease for an objective response rate of 14% and disease control rate of 49%

SpringWorks Therapeutics, Inc. announced that it has entered into a sponsored research agreement with Fred Hutchinson Cancer Research Center to further explore the ability of SpringWorks’ investigational gamma secretase inhibitor, nirogacestat, to modulate B-cell maturation antigen and potentiate BCMA-targeting therapies, including radioimmunotherapies, in a variety of preclinical and patient-derived multiple myeloma models developed by researchers at Fred Hutch.